Cryptogenic organizing pneumonia overview: Difference between revisions
| Line 36: | Line 36: | ||
Patients with [[cryptogenic organizing pneumonia]] usually appear in mild distress. On examination, the patient is usually febrile, in [[tachypnea]], [[tachycardia]] with the regular [[pulse]]. On lung auscultation there are bilateral vesicular [[breath sounds]], fine [[crackles]] and [[wheezing]] is heard. | Patients with [[cryptogenic organizing pneumonia]] usually appear in mild distress. On examination, the patient is usually febrile, in [[tachypnea]], [[tachycardia]] with the regular [[pulse]]. On lung auscultation there are bilateral vesicular [[breath sounds]], fine [[crackles]] and [[wheezing]] is heard. | ||
==Laboratory Findings=== | ===Laboratory Findings=== | ||
===Chest X Ray=== | ===Chest X Ray=== | ||
Findings on a chest X-ray in [[cryptogenic organizing pneumonia]] are [[Consolidation (medicine)|consolidation]], which may be unilateral/ bilateral, migratory and affects all lung zone.Foci of [[Granulation tissue|granulation]] tissue can also be seen. | |||
===Electrocardiogram=== | ===Electrocardiogram=== | ||
There are no ECG findings associated with [[cryptogenic organizing pneumonia]]. | There are no ECG findings associated with [[cryptogenic organizing pneumonia]]. | ||
Revision as of 00:16, 7 March 2018
|
Cryptogenic Organizing Pneumonia Microchapters |
|
Differentiating Cryptogenic organizing pneumonia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cryptogenic organizing pneumonia overview On the Web |
|
American Roentgen Ray Society Images of Cryptogenic organizing pneumonia overview |
|
Directions to Hospitals Treating Cryptogenic organizing pneumonitis |
|
Risk calculators and risk factors for Cryptogenic organizing pneumonia overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Cryptogenic organizing pneumonitis is a rapidly developing pneumonia-like illness characterised by lung inflammation and scarring that obstruct the small airways and air sacs of the lungs (alveoli). Its name is derived from the fact that it closely mimics pneumonia infections. (The term COP is used in Europe and BOOP in North America.)
Bronchiolitis obliterans organizing pneumonia is an inflammation of the bronchioles and surrounding tissue in the lungs. BOOP is often caused by a pre-existing chronic inflammatory disease like rheumatoid arthritis. In cases where no cause is found, the disease is called cryptogenic organizing pneumonia.
The clinical features and radiological imaging resemble infectious pneumonia. However, diagnosis is suspected after there is no response to multiple antibiotics, and blood and sputum cultures are negative for organisms.
Historical Perspective
Initial descriptions of organizing pneumonia can be traced back to 1877 Paris, in the lectures of J.M. Charcot. The first report of non-infectious organizing pneumonia without an identifiable underlying etiology was published in 1983. Soon after, the term "bronchiolitis obliterans organizing pneumonia (BOOP)" was introduced. This nomenclature was abandoned in 2002 by the American Thoracic Society/European Respiratory Society International Consensus Panel and the term cryptogenic organizing pneumonia was adopted.
Classification
There is no established system for the classification of cryptogenic organizing pneumonia.
Pathophysiology
Cryptogenic organizing pneumonia is an idiopathic diffuse interstitial lung disease that affects the distal bronchioles, respiratory bronchioles, alveolar ducts, and alveolar walls. The injury occurs within the alveolar wall. There is proliferation of granulation tissue which involves alveolar ducts and alveoli. There are 4 phases lead to the formation of mature fibrotic bud.
Causes
Differentiating Cryptogenic organizing pneumonia from Other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications, and Prognosis
Diagnosis
History and Symptoms
Patients with cryptogenic organizing pneumonia may have a positive history of connective tissue diseases, drug intake, malignancy and another interstitial lung disease. Common symptoms are a dry cough, shortness of breath, fever, fatigue and weight loss. Less common symptoms are hemoptysis, chest pain, and night sweats.
Physical Examination
Patients with cryptogenic organizing pneumonia usually appear in mild distress. On examination, the patient is usually febrile, in tachypnea, tachycardia with the regular pulse. On lung auscultation there are bilateral vesicular breath sounds, fine crackles and wheezing is heard.
Laboratory Findings
Chest X Ray
Findings on a chest X-ray in cryptogenic organizing pneumonia are consolidation, which may be unilateral/ bilateral, migratory and affects all lung zone.Foci of granulation tissue can also be seen.
Electrocardiogram
There are no ECG findings associated with cryptogenic organizing pneumonia.
CT
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
The mainstay of the therapy is pharmacotherapy. Corticosteroids are used as first-line treatment for patients with the symptomatic and progressive disease. Treatment is planned according to the severity of the disease. For treatment of mild disease is to monitor if there is no worsening of symptoms or pulmonary function. If there is worsening of symptoms, macrolides are used in the treatment of mild disease.For persistent or gradually worsening disease, corticosteroids are used for treatment and for severe disease cytotoxic agents are added. Relapses are common with corticosteriods therapy, azathioprine is used.
Surgery
Surgical intervention is not recommended for the management of cryptogenic organizing pneumonia. Resection of the solitary nodule is the treatment for focal organizing pneumonia.
Primary Prevention
Effective measures for the primary prevention of cryptogenic organizing pneumonia is the elimination of the cause and appropriate treatment.
Secondary Prevention
Effective measures for the secondary prevention of cryptogenic organizing pneumonia include educating the patient about the need for early treatment to prevent long term disabling bronchiolitis obliterans and interstitial fibrosis.